Structure, strategies and market power of Genomma Lab: study case

Main Article Content

José G Vargas-Hernández
Gabriela Muratalla Bautista

Abstract

In the present research work the subject of the structure, strategies and market power of Genomma Lab was addressed, so a descriptive and explanatory study was carried out describing the concepts related to the aforementioned elements and explaining the indexes of Herfindahl -Hirschman (IHH) and Pascual. The methodology used is the application of the indices which are a measure of the level of concentration existing in an industry. The IHH index is the sum of the square of the market shares of the different companies that operate in an industry. This is to delimit the Mexican pharmaceutical industry in a market structure. In the main results, it was identified that Genomma is a diversified company, that takes the best of each company and potentiates it, for that reason it fits in the majority of the models, since it is forced to act like monopoly, that is why in the Year 2012 was obtained in the index of IHH 0.01690 and in the Paschal index 0.00127, which is why it is the most representative of the companies, followed by Bayer with 0.0086 and 0.00033 respectively. In addition, you get the instability index is 0.0235 small, which means that market share has changed very little, all three indices show that the market is quite competitive, regardless of the number of companies. 

Article Details

Section
Monographic section
Author Biographies

José G Vargas-Hernández

Periférico Norte 799 Edificio G-201-7,  Núcleo Universitario Los Belenes CUCEA
Zapopan, Jalisco C.P. 45100; México
Tel y fax: +52(33) 37703340, 37703300 ext 25685
josevargas@cucea.udg.mx, jgvh0811@yahoo.com,jvargas2006@gmail.com

Gabriela Muratalla Bautista

Professor investigador

References

Cabral, L (1997) Economía Industrial, Aravaca Madrid, Mc Graw Hill, pp. 197
CANIFARMA. (2012), Censo de la industria farmacéutica en México. Cámara Nacional de la industria Farmacéutica, Consultado en abril 2016 http://www.canifarma.org.mx
Esquivel, E. (27 mayo 2013) La Industria Farmacéutica en México: un jugoso negocio con la salud. SDPnoticias recuperado de http://www.sdpnoticias.com/columnas/2013/05/27/la-industria-farmaceutica-en-mexico-un-jugoso-negocio-con-la-salud
Genomma Lab (2013), Reporte de sustentabilidad, Mexico DF. Recuperado de http://llorenteycuencamexico.com/genommaesr/wpcontent/uploads/2015/05/reporte-de-sustentabilidad-2013.pdf
Genoma Lab (2011), Reporte de Sustentabilidad, México DF. Recuperado de http://llorenteycuencamexico.com/genommaesr/wp-content/uploads/2015/05/genomma-lab-sustentabilidad-2011.pdf
HR, Ratings (7 de Junio de 2013), Genomma Lab Internacional, S.A.B. de C.V.; Calificación Corporativa, México DF. Recuperado de https://www.hrratings.com/pdf/GENOMMA%20LAB_HRR_6jun13_F.pdf
INEGI (2009);. Censos Económicos de 2009. Instituto Nacional de Estadística y Geografía, Consultado en Abril de 2016. http://www.inegi.org.mx/
INEGI (2013), Encuesta Mensual de la Industria Manufacturera : EMIM : SCIAN 2007 pp. 38. Instituto Nacional de Estadística y Geografía Recuperado de http://www.inegi.org.mx/prod_serv/contenidos/espanol/bvinegi/productos/encuestas/establecimientos/indus_manu/emin_scian/emin.pdf
Pérez, G. (2013) Inversión y comercio: Industria Farmacéutica, Secretaria de Economía; PROMEXICO. Recuperado de http://mim.promexico.gob.mx/work/sites/mim/resources/LocalContent/368/2/130820_DS_Farmaceutica_ESP.pdf
Vargas-Hernandez, J. G. (2014). Gestión estratégica de organizaciones. Buenos Aires. Insumos latinoamericanos.
Varian, H.R. (2010). Microeconomia intermedia. Un enfoque actual .España. Antoni Bosch Editor.